+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

All Ages
All Genders
ID04299022

Evaluating the Safety and Effectiveness of ViviGen Cellular Bone Matrix in Orthopaedic Fracture Care Through Prospective and Retrospective Data Collection

Led by LifeNet Health · Updated on 2026-09-15

250

Participants Needed

4

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of Vivigen Cellular Bone Matrix Vivigen in patients with orthopaedic trauma who need bone grafting for acute fractures, delayed healing, non-union fractures, or fusion procedures. This study includes both a prospective registry and retrospective data collection to gather comprehensive information about Vivigens use in these different fracture care settings. Participants receive Vivigen Cellular Bone Matrix or adjunct bone graft treatments depending on their fracture type and setting, including acute, delayed, non-union, or fusion scenarios. The study collects data from multiple centers and includes patients treated with Vivigen or adjunct grafts to understand real-world usage and outcomes. Participants will be assessed at hospital discharge and followed up at 6 weeks, 3 months, 6 months, 12 months, and 24 months after their treatment. Researchers will track the need for additional surgeries reintervention rate, bone fusion success, and patient-reported outcomes using the PROMIS scores over 24 months to evaluate treatment results and safety.

CONDITIONS

Brief Title

Safety, Efficacy, & Use of ViviGen Cellular Bone Matrix Allograft in Orthopaedic Fracture Care

Research Team

M

Monique Alston-Epps

K

Kimberly Dorsch

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here